Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: is it strictly necessary?
We identified the null variants *3,*4,*5,*6,*7 and *8 of the CYP2D6 gene [encoding for cytochrome P450 (debrisoquine hydroxylase)] in a group of 84 chronic-stay psychiatric inpatients with severe schizophrenia or related disorders and receiving treatment with one or more CYP2D6 substrates for years. We also studied a group of 100 healthy controls of similar ethnic origin (Spanish Caucasians). Three patients were poor metabolizers (PMs) for antipsychotic drugs according to their CYP2D6 genotype (i.e. homozygous for the *4 allele) but they exhibited no adverse drug reaction over the years despite chronic treatment with CYP2D6 substrates. We suggest that CYP2D6 genetic screening is more useful in other type of psychiatric patients, particularly in younger ones starting treatment protocols.
Fernández-Santander
Ana
A
Universidad Europea de Madrid, Madrid, Spain.
Santiago
Catalina
C
Díez-Durán
Sarai
S
González
María
M
de Castro
Emilia
E
Guijarro
Jorge
J
Bandrés
Fernando
F
Lucia
Alejandro
A
Gómez-Gallego
Félix
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D002908:Chronic Disease; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000235:genetics*
D019389:Cytochrome P-450 CYP2D6